Precision Biosensor（A335810）株式概要プレシジョン・バイオセンサー社は体外診断薬会社で、韓国で診断試薬や分析機器の製造、流通、販売を行っている。 詳細A335810 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去5年間で収益は年間19.2%減少しました。 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( ₩46B )すべてのリスクチェックを見るA335810 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩2.11k144.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8b30b2016201920222025202620282031Revenue ₩29.7bEarnings ₩4.0bAdvancedSet Fair ValueView all narrativesPrecision Biosensor, Inc. 競合他社KMSymbol: KOSDAQ:A083550Market cap: ₩41.7bWonbiogenSymbol: KOSDAQ:A307280Market cap: ₩52.7bHASSSymbol: KOSDAQ:A450330Market cap: ₩52.7bEOFLOWLtdSymbol: KOSDAQ:A294090Market cap: ₩52.3b価格と性能株価の高値、安値、推移の概要Precision Biosensor過去の株価現在の株価₩2,110.0052週高値₩4,500.0052週安値₩1,980.00ベータ0.401ヶ月の変化-8.86%3ヶ月変化-21.85%1年変化-16.77%3年間の変化-63.62%5年間の変化-87.09%IPOからの変化-93.51%最新ニュースお知らせ • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South KoreaNew Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).お知らせ • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.分析記事 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).最新情報をもっと見るRecent updatesお知らせ • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South KoreaNew Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).お知らせ • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.分析記事 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 06Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea分析記事 • Dec 16Precision Biosensor, Inc.'s (KOSDAQ:335810) Business Is Yet to Catch Up With Its Share PriceWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...分析記事 • Sep 10Some Confidence Is Lacking In Precision Biosensor, Inc. (KOSDAQ:335810) As Shares Slide 30%Precision Biosensor, Inc. ( KOSDAQ:335810 ) shareholders that were waiting for something to happen have been dealt a...分析記事 • Aug 26We Think Precision Biosensor (KOSDAQ:335810) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 02Subdued Growth No Barrier To Precision Biosensor, Inc.'s (KOSDAQ:335810) PriceWhen close to half the companies in the Medical Equipment industry in Korea have price-to-sales ratios (or "P/S") below...New Risk • May 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.4b market cap, or US$36.2m).Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 07Precision Biosensor, Inc. announced that it expects to receive KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and another investorPrecision Biosensor, Inc. announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 3,000,000,000 on February 6, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 1) for KRW 500,000,000 and JB Mezzanine New Technology Business Investment No. 2 for KRW 1,500,000,000. The bonds bear zero coupon rate and 3% maturity rate and matures on February 9, 2029. The transaction has been approved by the shareholders of the company and is expected to close on February 8, 2024. The bonds are 100% convertible into 596,658 shares at a fixed conversion price of KRW 5,028 from February 8, 2025 to January 8, 2029.Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).株主還元A335810KR Medical EquipmentKR 市場7D0.5%1.5%4.6%1Y-16.8%-3.6%186.7%株主還元を見る業界別リターン: A335810過去 1 年間で-3.6 % の収益を上げたKR Medical Equipment業界を下回りました。リターン対市場: A335810は、過去 1 年間で186.7 % のリターンを上げたKR市場を下回りました。価格変動Is A335810's price volatile compared to industry and market?A335810 volatilityA335810 Average Weekly Movement7.4%Medical Equipment Industry Average Movement9.1%Market Average Movement9.4%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%安定した株価: A335810 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A335810の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200998Han-Shin Kimprecision-bio.comプレシジョン・バイオセンサー社は体外診断薬会社で、韓国で診断試薬や分析機器を製造、流通、販売している。同社は心臓、感染症、脳、大腸、妊娠、ビタミンD欠乏症用のカートリッジやイムノクロマト分析装置を提供している。また、試薬反応を活性化するためのサーモスタット装置、IQC分析装置も提供している。同社は2015年に設立され、韓国のテジョンに本社を置いている。もっと見るPrecision Biosensor, Inc. 基礎のまとめPrecision Biosensor の収益と売上を時価総額と比較するとどうか。A335810 基礎統計学時価総額₩46.31b収益（TTM）-₩7.87b売上高(TTM)₩22.34b2.1xP/Sレシオ-5.9xPER（株価収益率A335810 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A335810 損益計算書（TTM）収益₩22.34b売上原価₩14.30b売上総利益₩8.04bその他の費用₩15.91b収益-₩7.87b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-358.73グロス・マージン35.98%純利益率-35.25%有利子負債／自己資本比率30.3%A335810 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 13:31終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Precision Biosensor, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea
New Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).
お知らせ • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.
分析記事 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).
お知らせ • Mar 07Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026Precision Biosensor, Inc., Annual General Meeting, Mar 25, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea
New Risk • Nov 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.4b market cap, or US$35.6m).
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₩32.7b market cap, or US$22.6m).
お知らせ • Nov 03Precision Biosensor, Inc. announced that it has received KRW 17.00000112 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.On November 3, 2025, Precision Biosensor, Inc announced that it has raised KRW 17,000,001,120 in funding and closed the transaction.
分析記事 • Jun 19Does Precision Biosensor (KOSDAQ:335810) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩1.8b free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩40.8b market cap, or US$29.6m).
Reported Earnings • Mar 25Full year 2024 earnings released: ₩629 loss per share (vs ₩387 loss in FY 2023)Full year 2024 results: ₩629 loss per share (further deteriorated from ₩387 loss in FY 2023). Revenue: ₩19.1b (down 6.2% from FY 2023). Net loss: ₩7.31b (loss widened 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 06Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025Precision Biosensor, Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 35, techno 9-ro, yuseong-gu, daejeon South Korea
分析記事 • Dec 16Precision Biosensor, Inc.'s (KOSDAQ:335810) Business Is Yet to Catch Up With Its Share PriceWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...
分析記事 • Sep 10Some Confidence Is Lacking In Precision Biosensor, Inc. (KOSDAQ:335810) As Shares Slide 30%Precision Biosensor, Inc. ( KOSDAQ:335810 ) shareholders that were waiting for something to happen have been dealt a...
分析記事 • Aug 26We Think Precision Biosensor (KOSDAQ:335810) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jul 02Subdued Growth No Barrier To Precision Biosensor, Inc.'s (KOSDAQ:335810) PriceWhen close to half the companies in the Medical Equipment industry in Korea have price-to-sales ratios (or "P/S") below...
New Risk • May 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩7.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩7.6b free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.4b market cap, or US$36.2m).
Reported Earnings • Mar 22Full year 2023 earnings released: ₩387 loss per share (vs ₩590 loss in FY 2022)Full year 2023 results: ₩387 loss per share (improved from ₩590 loss in FY 2022). Revenue: ₩20.4b (flat on FY 2022). Net loss: ₩4.49b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 07Precision Biosensor, Inc. announced that it expects to receive KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. and another investorPrecision Biosensor, Inc. announced a private placement to issue Series 3 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 3,000,000,000 on February 6, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. for KRW 1,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 1) for KRW 500,000,000 and JB Mezzanine New Technology Business Investment No. 2 for KRW 1,500,000,000. The bonds bear zero coupon rate and 3% maturity rate and matures on February 9, 2029. The transaction has been approved by the shareholders of the company and is expected to close on February 8, 2024. The bonds are 100% convertible into 596,658 shares at a fixed conversion price of KRW 5,028 from February 8, 2025 to January 8, 2029.
Reported Earnings • Mar 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ₩368 loss per share (up from ₩550 loss in FY 2020). Revenue: ₩15.9b (up 83% from FY 2020). Net loss: ₩4.15b (loss narrowed 16% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₩58.00 loss per share (vs ₩36.63 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩4.67b (down 8.1% from 3Q 2020). Net loss: ₩655.8m (down 280% from profit in 3Q 2020).
